Quick Answer
NIKA PHARMACEUTICALS, INC reported Net Income of -$76.4 thousand for fiscal year 2025.
NIKA PHARMACEUTICALS, INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$76.4K +20.2% |
-$95.8K -47.8% |
-$64.8K +98.0% |
-$3.18M -21540.3% |
-$14.7K -65.2% |
-$8.9K |
| Diluted EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total Assets | $21.0K +17.1% |
$17.9K -8.5% |
$19.6K +2168.1% |
$864.00 +116.5% |
$399.00 -75.2% |
$1.6K |
| Cash and Equivalents | $1.9K -9.3% |
$2.1K -89.4% |
$19.6K +2168.1% |
$864.00 +116.5% |
$399.00 -75.2% |
$1.6K |
| Stockholders Equity | -$297.6K -34.5% |
-$221.2K -169.3% |
-$82.1K -374.4% |
-$17.3K +26.7% |
-$23.6K -165.2% |
-$8.9K |
| Operating Income | -$76.4K +20.2% |
-$95.8K -47.8% |
-$64.8K +98.0% |
-$3.18M -21540.3% |
-$14.7K -65.2% |
-$8.9K |
| Shares Outstanding | 1.05B +0.0% |
1.05B +19.6% |
876.09M +0.0% |
876.09M +121.2% |
396.09M +2900.0% |
13.20M +0.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2024 | $156.00 | — | — |
| Net Income | September 30, 2025 | -$8.0K | +4.4% | +56.5% |
| Diluted EPS | September 30, 2025 | $0.00 | — | — |
| Total Assets | September 30, 2025 | $23.6K | +1604.5% | -25.3% |
| Cash and Equivalents | September 30, 2025 | $6.3K | +353.6% | -59.7% |
| Stockholders Equity | September 30, 2025 | -$260.5K | -30.0% | -3.2% |
| Operating Income | September 30, 2025 | -$8.0K | +4.4% | +56.5% |
| Shares Outstanding | September 30, 2025 | 1.04B | +2.1% | +1.3% |
- NIKA PHARMACEUTICALS, INC reported Net Income of -$76.4 thousand for fiscal year 2025.
- NIKA PHARMACEUTICALS, INC showed an increase of +20.2% in Net Income compared to the prior fiscal year.
- NIKA PHARMACEUTICALS, INC reported Diluted EPS of $0.00 per share for fiscal year 2025.
- NIKA PHARMACEUTICALS, INC reported Total Assets of $21.0 thousand for fiscal year 2025.
- NIKA PHARMACEUTICALS, INC showed an increase of +17.1% in Total Assets compared to the prior fiscal year.
- NIKA PHARMACEUTICALS, INC reported Cash and Equivalents of $1.9 thousand for fiscal year 2025.
- NIKA PHARMACEUTICALS, INC showed a decrease of -9.3% in Cash and Equivalents compared to the prior fiscal year.
- NIKA PHARMACEUTICALS, INC reported Stockholders Equity of -$297.6 thousand for fiscal year 2025.
- NIKA PHARMACEUTICALS, INC showed a decrease of -34.5% in Stockholders Equity compared to the prior fiscal year.
- NIKA PHARMACEUTICALS, INC reported Operating Income of -$76.4 thousand for fiscal year 2025.
- NIKA PHARMACEUTICALS, INC showed an increase of +20.2% in Operating Income compared to the prior fiscal year.
- NIKA PHARMACEUTICALS, INC reported Shares Outstanding of 1.05 billion shares for fiscal year 2025.
- NIKA PHARMACEUTICALS, INC showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: